Abstract
BackgroundImmunologically “cold” tumors, which lack tumor infiltrating lymphocytes (TILs), are minimally responsive to immune checkpoint blockade (ICB). VAX014 is a novel clinical stage targeted oncolytic agent based on recombinant bacterial...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have